Human papillomavirus and cervical cancer
Main Article Content
Abstract
Background: According to the World Health Organization, human papillomavirus(HPV) causes cervical cancer, which is the fourth most common cancer in women, with an estimated 266,000 deaths and 528,000 new cases in 2012. Usually, HPV infections cause no symptoms but it is also reported that 99% cervical cancer cases are linked to genital infection with HPV and it is the most common viral infection of the reproductive tract.
Aim: The aim of the study is to review the literature to describe what research has been done and what can be the future prospect.
Methods: To search for the literature search engine, PubMed and Google were searched by inputting different key words, for example, HPV and cervical cancer. Studies considered were broadly associated with either HPV and cervical cancer or its worldwide scenario and socio-economic status.
Results: Considered studies showed that Genital HPV is the most common sexually transmitted infection in the United States, whereas a considerable number i.e., 90% cases of cervical cancer, HPV was detected. The largest proportion attributable to HPV reported were about 75%, 70%, 70% and 60% of vaginal cancers, oropharyngeal cancers, vulvar cancers and penile cancers, respectively. Various identified risk factors as well as different suggested methods are also described to protect against HPV.
Conclusion: We may conclude that as it is sexually transmitted infection and causes no symptoms, so proper care should be taken in intimate hygiene management.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The journal grants the right to make small numbers of printed copies for their personal non-commercial use under Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported License.
References
1. zur Hausen H. Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer 2002;2:342‑50.
2. Ramqvist T, Grün N, Dalianis T. Human papillomavirus and tonsillar and base of tongue cancer. Viruses 2015;7:1332‑43.
3. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non‑cancerous HPV‑related conditions: HPV‑6/11 disease. Vaccine
2006;24 Suppl 3:S3/35‑41.
4. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005;6:204.
5. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: A meta‑analysis. Br J Cancer 2003;88:63‑73.
6. Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009;124:2375‑83.
7. Workowski KA. Centers for Disease Control and Prevention (CDC): Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010;59:1‑110.
8. Mammas IN, Sourvinos G, Spandidos DA. The paediatric story of human papillomavirus (Review). Oncol Lett 2014;8:502‑6.
9. Mammas IN, Vageli D, Spandidos DA. Geographic variations of human papilloma virus infection and their possible impact on the effectiveness of the vaccination programme. Oncol Rep 2008;20:141‑5.
10. Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015;64:1‑37.
11. Satterwhite CL, Torrone E, Meites E, Dunne EF, Mahajan R, Ocfemia MC, et al. Sexually transmitted infections among US women and men: Prevalence and incidence estimates, 2008. Sex Transm Dis 2013;40:187‑93.
12. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al. The biology and life‑cycle of human papillomaviruses. Vaccine 2012;30 Suppl 5:F55‑70.
13. International Human Papillomavirus Reference Center. Reference clones, Stockholm: Karolinska Institutet; Updated 2016.
14. Nielsen A, Kjaer SK, Munk C, Iftner T. Type‑specific HPV infection and multiple HPV types: Prevalence and risk factor profile in nearly 12,000 younger and older Danish women. Sex Transm Dis 2008;35:276‑82.
15. Skaaby S, Kofoed K. Anogenital warts in Danish men who have sex with men. Int J STD AIDS 2011;22:214‑7.
16. Owusu‑Edusei K Jr., Chesson HW, Gift TL, Tao G, Mahajan R, Ocfemia MC, et al. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis 2013;40:197‑201.
17. Tota JE, Chevarie‑Davis M, Richardson LA, Devries M, Franco EL. Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies. Prev Med 2011;53 Suppl 1:S12‑21.
18. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29:4294‑301.
19. Chouhy D, Bolatti EM, Pérez GR, Giri AA. Analysis of the genetic diversity and phylogenetic relationships of putative human papillomavirus types. J Gen Virol 2013;94:2480‑8.
20. de Villiers EM. Cross‑roads in the classification of papillomaviruses. Virology 2013;445:2‑10.
21. Smelov V, Hanisch R, McKay‑Chopin S, Sokolova O, Eklund C, Komyakov B, et al. Prevalence of cutaneous beta and gamma human papillomaviruses in the anal canal of men who have sex with women. Papillomavirus Res 2017;3:66‑72.
22. Ronco G, Arbyn M, Segnan N. Cervical screening according to age and HPV status. BMJ 2009;339:b3005.
23. Moscicki AB, Widdice L, Ma Y, Farhat S, Miller‑Benningfield S, Jonte J, et al. Comparison of natural histories of human papillomavirus detected by clinician‑ and self‑sampling. Int J Cancer 2010;127:1882‑92.
24. Torres M, Gheit T, McKay‑Chopin S, Rodríguez C, Romero JD, Filotico R, et al. Prevalence of beta and gamma human papillomaviruses in the anal canal of men who have sex with men is influenced by HIV status. J Clin Virol 2015;67:47‑51.
25. Donà MG, Gheit T, Latini A, Benevolo M, Torres M, Smelov V, et al. Alpha, beta and gamma Human Papillomaviruses in the anal canal of
HIV‑infected and uninfected men who have sex with men. J Infect 2015;71:74‑84.
26. Pierce CampbellCM, Messina JL, Stoler MH, Jukic DM, Tommasino M, Gheit T, et al. Cutaneous human papillomavirus types detected on the
surface of male external genital lesions: A case series within the HPV Infection in Men Study. J Clin Virol 2013;58:652‑9.
27. Sichero L, El‑Zein M, Nunes EM, Ferreira S, Franco EL, Villa LL, et al. Cervical infection with cutaneous beta and mucosal alpha papillomaviruses. Cancer Epidemiol Biomarkers Prev 2017;26:1312‑20.
28. BottalicoD, ChenZ, DunneA, Ostoloza J, McKinney S, SunC, et al. The oral cavity contains abundant known and novel human papillomaviruses
from the Betapapillomavirus and Gammapapillomavirus genera. J Infect Dis 2011;204:787‑92.
29. Paolini F, Rizzo C, Sperduti I, Pichi B, Mafera B, Rahimi SS, et al. Both mucosal and cutaneous papillomaviruses are in the oral cavity but only alpha genus seems to be associated with cancer. J Clin Virol 2013;56:72‑6.
30. Forslund O, Johansson H, Madsen KG, Kofoed K. The nasal mucosa contains a large spectrum of human papillomavirus types from the
Betapapillomavirus and Gammapapillomavirus genera. J Infect Dis 2013;208:1335‑41.
31. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: Recommendations of the
Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014;63:1‑30.
32. Parkin DM, Bray F. Chapter 2: The burden of HPV‑related cancers. Vaccine 2006;24 Suppl 3:S3/11‑25.
33. Hartwig S, Syrjänen S, Dominiak‑Felden G, Brotons M, Castellsagué X. Estimation of the epidemiological burden of human papillomavirus‑related cancers and non‑malignant diseases in men in Europe: A review. BMC Cancer 2012;12:30.
34. Mehanna H, Jones TM, Gregoire V, Ang KK. Oropharyngeal carcinoma related to human papillomavirus. BMJ 2010;340:c1439.
35. The Joint Committee on Vaccination and Immunisation (JCVI) Interim Statement on Extending HPV Vaccination to Adolescent Boys; 2017.
36. Newman PA, Lacombe‑Duncan A. Human papillomavirus vaccination for men: Advancing policy and practice. Future Virol 2014;9:1033‑47.
37. Gottvall M, Stenhammar C, Grandahl M. Parents’ views of including young boys in the Swedish national school‑based HPV vaccination
programme: A qualitative study. BMJ Open 2017;7:e014255.
38. Muhwezi WW, Banura C, Turiho AK, Mirembe F. Parents’ knowledge, risk perception and willingness to allow young males to receive human
papillomavirus(HPV) vaccines in Uganda. PLoS One 2014;9:e106686.
39. Lee Mortensen G, Adam M, Idtaleb L. Parental attitudes towards male human papillomavirus vaccination: A pan‑European cross‑sectional
survey. BMC Public Health 2015;15:624.
40. Saraiya M, Unger ER, Thompson TD, Lynch CF, Hernandez BY, Lyu CW, et al. US assessment of HPV types in cancers: Implications for current and 9‑valent HPV vaccines. J Natl Cancer Inst 2015;107:djv086.
41. Sherman SM, Nailer E, Minshall C, Coombes R, Cooper J, Redman CW. Awareness and knowledge of HPV and cervical cancer in female
students: A survey (with a cautionary note). J Obstet Gynaecol 2016;36:76‑80.
42. Perez S, Tatar O, Ostini R, Shapiro GK, Waller J, Zimet G, et al. Extending and validating a human papillomavirus (HPV) knowledge measure in a national sample of Canadian parents of boys. Prev Med 2016;91:43‑9.
43. Waller J, Ostini R, Marlow LA, McCaffery K, Zimet G. Validation of a measure of knowledge about human papillomavirus(HPV) using item
response theory and classical test theory. Prev Med 2013;56:35‑40.
44. Perez S, Shapiro GK, Tatar O, Joyal‑Desmarais K, Rosberger Z. Development and validation of the human papillomavirus attitudes and beliefs scale in a national Canadian sample. Sex Transm Dis 2016;43:626‑32.
45. Fu TC, Fu Xi L, Hulbert A, Hughes JP, Feng Q, Schwartz SM, et al. Short‑term natural history of high‑risk human papillomavirus infection in mid‑adult women sampled monthly. Int J Cancer 2015;137:2432‑42.
46. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010;401:70‑9.
47. Burk RD, Harari A, Chen Z. Human papillomavirus genome variants. Virology 2013;445:232‑43.
48. Pande S, Jain N, Prusty BK. Human papillomavirus type 16 variant analysis of E6, E7, and L1 genes and long control region in biopsy samples from cervical cancer patients in North India. J Clin Microbiol 2008;46:10600‑66.
49. Ramas V, Mirazo S, Bonilla S, Ruchansky D, Arbiza J. Analysis of human papillomavirus 16 E6, E7 genes and Long Control Region in cervical samples from Uruguayan women. Gene 2018;654:103‑9.
50. Lehoux M, D’Abramo CM, Archambault J. Molecular mechanisms of human papillomavirus‑induced carcinogenesis. Public Health Genomics 2009;12:268‑80.
51. Insinga RP, Dasbach EJ, Elbasha EH. Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: A critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis 2009;9:119.
52. Nunes EM, Sudenga SL, Gheit T, Tommasino M, Baggio ML, Ferreira S, et al. Diversity of beta‑papillomavirus at anogenital and oral anatomic sites of men: The HIM Study. Virology 2016;495:33‑41.
53. Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T. Bead‑based multiplex genotyping of human papillomaviruses. J Clin
Microbiol 2006;44:504‑12.
54. Gheit T, Billoud G, de Koning MN, Gemignani F, Forslund O, Sylla BS, et al. Development of a sensitive and specific multiplex PCR method combined with DNA microarray primer extension to detect Betapapillomavirus types. J Clin Microbiol 2007;45:2537‑44.
55. ICO Information Centre on HPV and Cancer. Human Papillomavirus and Related Diseases in India (Summary Report 2014). ICO Information Centre on HPV and Cancer; 2014. p. 8‑22.
56. Sreedevi A, Javed R, Dinesh A. Epidemiology of cervical cancer with special focus on India. Int J Womens Health 2015;7:405‑14.
57. Dhananjaya S. Current status of cancer burden: Global and Indian scenario. Biomed Res J 2014;1:1‑5.
58. IARC Working Group on the Evaluation of Carcinogenic Risk to Humans. Biological Agents. IARC Monographs on the Evaluation of
Carcinogenic Riskto Humans, No. 100B. Lyon: IARC; 2012.
59. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive
cervical cancer worldwide. J Pathol 1999;189:12‑9.
60. Ferenczy A, Franco E. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol 2002;3:11‑6.
61. Sherman SM, NailerE. Attitudes towards and knowledge about Human Papillomavirus (HPV) and the HPV vaccination in parents of teenage
boys in the UK. PLoS One 2018;13:e0195801.
62. Yarbro CH. Cancer Nursing: Principles and Practice. 7th ed. Jones & Bartlett Learning. Burlington, MA: Jones & Bartlett Publishers; 2010.
63. Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004;4:46‑54.
64. Aggarwal R, Gupta S, Nijhawan R, Suri V, Kaur A, Bhasin V, et al. Prevalence of high‑‑risk human papillomavirus infections in women with benign cervical cytology: A hospital based study from North India. Indian J Cancer 2006;43:110‑6.
65. Miller D, Okolo CA, Mirabal Y, Guillaud M, Arulogun OS, Oladepo O, et al. Knowledge dissemination and evaluation in a cervical cancer
screening implementation program in Nigeria. Gynecol Oncol 2007;107:S196‑207.
66. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: A summary of meta‑analyses. Vaccine 2006;24 Suppl 3:S3/78‑89.
67. Bang RA, Bang AT, Baitule M, Choudhary Y, Sarmukaddam S, Tale O. High prevalence of gynaecological diseases in rural Indian women.
Lancet 1989;1:85‑8.
68. Basu PS, Sankaranarayanan R, Mandal R, Roy C, Das P, Choudhury D, et al. Visual inspection with acetic acid and cytology in the early
detection of cervical neoplasia in Kolkata, India. Int J Gynecol Cancer 2003;13:626‑32.
69. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec 2014;89:465‑91.
70. Schensul SL, Mekki‑Berrada A, Nastasi BK, Singh R, Burleson JA, Bojko M. Men’s extramarital sex, marital relationships and sexual risk in urban poor communities in India. J Urban Health 2006;83:614‑24.
71. Sellors J, Sankaranarayanan R. Colposcopy and Treatment of Cervical Intraepithelial Neoplasia: A Beginners’ Manual. Lyon: IARC Press;
2003.
72. Sen A. The Delivery of Primary Health Services. A Study in West Bengal and Jharkhand. The Pratichi Health Report Number 1. TLM Books with Pratichi (India) Trust; 2005.
73. Shanta V. Perspectives in Cervical Cancer prevention in India. The International Network for Cancer Treatment and Research; 2003.
74. Shastri SS, Dinshaw K, Amin G, Goswami S, Patil S, Chinoy R, et al. Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India. Bull World Health Organ 2005;83:186‑94.
75. Sankaranarayanan R, Budukh AM, Rajkumar R. Effective screening programmes for cervical cancer in low‑and middle‑income developing
countries. Bull World Health Organ 2001;79:954‑62.
76. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009;360:1385‑94.
77. Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: A cluster‑randomised trial. Lancet 2007;370:398‑406.
78. Plotkin M, Besana GV, Yuma S, Kim YM, Kulindwa Y, Kabole F, et al. Integrating HIV testing into cervical cancer screening in Tanzania: An
analysis of routine service delivery statistics. BMC Womens Health 2014;14:120.
79. Finocchario‑Kessler S, Wexler C, Maloba M, Mabachi N, Ndikum‑Moffor F, Bukusi E. Cervical cancer prevention and treatment research in Africa: Asystematic review from a public health perspective. BMC Womens Health 2016;16:29.
80. Abotchie PN, Shokar NK. Cervical cancer screening among college students in Ghana: Knowledge and health beliefs. Int J Gynecol Cancer
2009;19:412‑6.
81. Maree JE, Lu XM, Wright SC. Combining breast and cervical screening in an attempt to increase cervical screening uptake. An intervention study in a South African context. Eur J Cancer Care (Engl) 2012;21:78‑86.
82. Mingo AM, Panozzo CA, DiAngi YT, Smith JS, Steenhoff AP, Ramogola‑Masire D, et al. Cervical cancer awareness and screening in Botswana. Int J Gynecol Cancer 2012;22:638‑44.
83. Mupepi SC, Sampselle CM, Johnson TR. Knowledge, attitudes, and demographic factors influencing cervical cancer screening behavior of Zimbabwean women. J Womens Health (Larchmt) 2011;20:943‑52.
84. Tebeu PM, Major AL, Rapiti E, Petignat P, Bouchardy C, Sando Z, et al. The attitude and knowledge of cervical cancer by Cameroonian
women; a clinical survey conducted in Maroua, the capital of Far North province of Cameroon. Int J Gynecol Cancer 2008;18:761‑5.
85. Lăără E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: Association with organised screening
programmes. Lancet 1987;1:1247‑9.
86. Laikangbam P, Sengupta S, Bhattacharya P, Duttagupta C, Dhabali Singh T, Verma Y, et al. Acomparative profile of the prevalence and age distribution of human papillomavirus type 16/18 infections among three states of India with focus on northeast India. Int J Gynecol Cancer 2007;17:107‑17.
87. Legood R, Gray AM, Mahé C, Wolstenholme J, Jayant K, Nene BM, et al. Screening for cervical cancer in India: How much will it cost? A trial based analysis of the cost per case detected. Int J Cancer 2005;117:981‑7.
88. Londhe M, George SS, Seshadri L. Detection of CIN by naked eye visualization after application of acetic acid. Indian J Cancer 1997;34:88‑91.
89. Current Trends in Biotechnology and Pharmacy Mandal R, Mittal S, Basu P. 8:4; October, ISSN 0973-8916 (Print), 2230-7303 (Online).
90. Ezechi OC, Gab‑Okafor CV, Ostergren PO, Odberg Pettersson K. Willingness and acceptability of cervical cancer screening among HIV
positive Nigerian women. BMC Public Health 2013;13:46.
91. Rosser JI, Njoroge B, Huchko MJ. Cervical cancer screening knowledge and behavior among women attending an Urban HIV clinic in Western
Kenya. J Cancer Educ 2015;30:567‑72.